What is the equity of Biocept this year?
Biocept has equity of 8.86 M USD this year.
Biocept Equity 2025
Biocept Equity
8.86 M USD
Ticker
BIOC
ISIN
US09072V5012
WKN
A2QEQE
In 2025, Biocept's equity was 8.86 M USD, a 0% increase from the 0 USD equity in the previous year.
Biocept Aktienanalyse
What does Biocept do?
Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Biocept's Equity
Biocept's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biocept's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Biocept's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Biocept's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Biocept’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Biocept stock
What was the equity of Biocept compared to the previous year?
The equity of Biocept has increased/decreased by 0% decreased compared to the previous year.
What impact does a high equity have on investors of Biocept?
A high equity is advantageous for investors of Biocept as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Biocept?
A low equity can be a risk for investors of Biocept, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Biocept affect the company?
An increase in equity of Biocept can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Biocept affect the company?
A reduction in equity of Biocept can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Biocept?
Some factors that can affect the equity of Biocept include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Biocept so important for investors?
The equity of Biocept is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Biocept take to change the equity?
To change equity, Biocept can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Biocept pay?
Over the past 12 months, Biocept paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocept is expected to pay a dividend of 0 USD.
What is the dividend yield of Biocept?
The current dividend yield of Biocept is .
When does Biocept pay dividends?
Biocept pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biocept?
Biocept paid dividends every year for the past 0 years.
What is the dividend of Biocept?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biocept located?
Biocept is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biocept kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biocept from 9/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2025.
When did Biocept pay the last dividend?
The last dividend was paid out on 9/29/2025.
What was the dividend of Biocept in the year 2024?
In the year 2024, Biocept distributed 0 USD as dividends.
In which currency does Biocept pay out the dividend?
The dividends of Biocept are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biocept
Our stock analysis for Biocept Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
